Oncternal Therapeutics

125 articles with Oncternal Therapeutics

• Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results

  3/9/2023

  Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported fourth quarter and full year 2022 financial results.

• Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results

  3/2/2023

  Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2022 financial results after the U.S. financial markets close on Thursday, March 9, 2023.

• Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - March 01, 2023

  3/1/2023

  Oncternal Therapeutics, Inc. announced that it has granted an inducement award to one new employee, Yelena Tsabur, who joined Oncternal as Associate Clinical Trial Manager.

• Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - February 01, 2023

  2/1/2023

  Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that it has granted an inducement award to one new employee, Jennifer Neumann, who joined Oncternal as Director, Clinical Data Management.

• Oncternal Therapeutics Announces the Appointment of Jill DeSimone to the Board of Directors

  1/4/2023

  Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Jill DeSimone to its board of directors.

• Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - Jan 03, 2023

  1/3/2023

  Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that it has granted inducement awards to two new non-executive employees.

• Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2022

  12/10/2022

  Oncternal Therapeutics, Inc. announced updated interim clinical data from ongoing Phase 1/2 Study CIRM-0001 in an oral presentation at the American Society of Hematology 2022 Annual Meeting.

• Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

  12/1/2022

  Oncternal Therapeutics, Inc. today announced that it has granted an inducement award to one new employee, James Robinson, who joined Oncternal as Head of Biometrics & Data Sciences.

• Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - November 14, 2022

  11/14/2022

  Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that it has granted an inducement award to one new employee, Edward C. Dow, who joined Oncternal as Vice President, Clinical Development.

• Oncternal Therapeutics to Present Updated Interim Phase 1/2 Data for Zilovertamab in Combination with Ibrutinib in an Oral Session at ASH 2022

  11/3/2022

  Oncternal Therapeutics, Inc. announced that interim clinical data from the ongoing Phase 1/2 Study CIRM-0001 will be presented in an Oral Session at the American Society of Hematology Annual Meeting and Exposition taking place on December 10-13, 2022, in New Orleans, Louisiana.

• Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results

  11/3/2022

  Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, provided a business update and reported financial results for the third quarter of 2022.

• Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results

  10/27/2022

  Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report third quarter 2022 financial results after the U.S. financial markets close on Thursday, November 3, 2022.

• Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - October 03, 2022

  10/3/2022

  Oncternal Therapeutics, Inc. announced that it has granted an inducement award to one new employee, Ariadne Jerue, who joined Oncternal as Associate Director, Clinical Operations.

• Oncternal Therapeutics Receives IND Clearance for ONCT-808, its autologous CAR T Product Candidate Targeting ROR1 for the Treatment of Aggressive B Cell Lymphoma

  10/3/2022

  Oncternal Therapeutics, Inc. announced the receipt of a ‘Study May Proceed’ letter from the U.S. Food and Drug Administration, 30 days after submitting its Investigational New Drug application for a Phase 1/2 dose escalation study of ONCT-808, an autologous chimeric antigen receptor T therapy targeting ROR1, in patients with aggressive B cell non-Hodgkin’s lymphoma, including those who have failed previous CD19 CAR T treatment.

• Oncternal Therapeutics Initiates Global Registrational Phase 3 Study of Zilovertamab for Patients with MCL

  9/27/2022

  Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the initiation of its Phase 3 global registrational study of zilovertamab, ZILO-301 (NCT05431179), for the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL).

• Oncternal Therapeutics to Participate in the Cantor Oncology, Hematology & HemeOnc Conference

  9/23/2022

  Oncternal Therapeutics, Inc. today announced that management will participate in the Cantor Oncology, Hematology & HemeOnc Conference on Wednesday, September 28, 2022 at the NY Palace Hotel in New York City.

• Oncternal Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

  9/7/2022

  Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the H.C. Wainwright 24th Annual Global Investment Conference to be held September 12-14, 2022.

• Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results

  8/9/2022

  Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported financial results for the second quarter of 2022.

• Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results

  8/2/2022

  Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2022 financial results after the U.S. financial markets close on Tuesday, August 9, 2022.

• Oncternal Therapeutics Announces Clinical Trial Collaboration to Advance Zilovertamab Phase 3 Study in combination with Ibrutinib for Patients with MCL

  7/14/2022

  Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced it entered into a clinical trial collaboration with Pharmacyclics, an AbbVie company, that includes supply of ibrutinib for its Phase 3 clinical trial.